NDC 61755-019

Inmazeb

Atoltivimab, Maftivimab, And Odesivimab-ebgn

Inmazeb is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Regeneron Pharmaceuticals, Inc.. The primary component is Atoltivimab; Maftivimab; Odesivimab.

• Product ID: 61755-019_1fc04220-a793-4dd3-812e-26389d422d3b
• NDC: 61755-019
• Product Type: Human Prescription Drug
• Proprietary Name: Inmazeb
• Generic Name: Atoltivimab, Maftivimab, And Odesivimab-ebgn
• Dosage Form: Injection, Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2021-07-29
• Marketing Category: BLA /
• Application Number: BLA761169
• Labeler Name: Regeneron Pharmaceuticals, Inc.
• Substance Name: ATOLTIVIMAB; MAFTIVIMAB; ODESIVIMAB
• Active Ingredient Strength: 483 mg/14.5mL; mg/14.5mL; mg/14.5mL
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 61755-019-01

1 VIAL, SINGLE-DOSE in 1 CARTON (61755-019-01) > 14.5 mL in 1 VIAL, SINGLE-DOSE (61755-019-00)

• Marketing Start Date: 2021-07-29
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "Inmazeb" or generic name "Atoltivimab, Maftivimab, And Odesivimab-ebgn"

NDC	Brand Name	Generic Name
61755-018	Inmazeb	atoltivimab, maftivimab, and odesivimab-ebgn
61755-019	Inmazeb	atoltivimab, maftivimab, and odesivimab-ebgn